Xue Yingfei, Zhai Jie
Tianjin University, School of Pharmaceutical Science and Technology (SPST) Tianjin 300072, China.
Department of Breast Surgical Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences Hangzhou 310022, Zhejiang, China.
Int J Clin Exp Pathol. 2024 Jul 15;17(7):189-207. doi: 10.62347/HGNI4903. eCollection 2024.
Cell cycle-dependent protein kinase 4/6 (CDK4/6) is a crucial kinase that regulates the cell cycle, essential for cell division and proliferation. Hence, combining CDK4/6 inhibitors with other anti-tumor drugs is a pivotal clinical strategy. This strategy can efficiently inhibit the growth and division of tumor cells, reduce the side effects, and improve the quality of life of patients by reducing the dosage of combined anticancer drugs. Furthermore, the combination therapy strategy of CDK4/6 inhibitors could ameliorate the drug resistance of combined drugs and overcome the CDK4/6 resistance caused by CDK4/6 inhibitors. Various tumor treatment strategies combined with CDK4/6 inhibitors have entered the clinical trial stage, demonstrating their substantial clinical potential. This study reviews the research progress of CDK4/6 inhibitors from 2018 to 2022, the related resistance mechanism of CDK4/6 inhibitors, and the strategy of combination medication.
细胞周期蛋白依赖性激酶4/6（CDK4/6）是一种调节细胞周期的关键激酶，对细胞分裂和增殖至关重要。因此，将CDK4/6抑制剂与其他抗肿瘤药物联合使用是一种关键的临床策略。该策略可有效抑制肿瘤细胞的生长和分裂，减少副作用，并通过降低联合抗癌药物的剂量提高患者的生活质量。此外，CDK4/6抑制剂的联合治疗策略可改善联合用药的耐药性，并克服由CDK4/6抑制剂引起的CDK4/6耐药性。多种与CDK4/6抑制剂联合的肿瘤治疗策略已进入临床试验阶段，显示出其巨大的临床潜力。本研究综述了2018年至2022年CDK4/6抑制剂的研究进展、CDK4/6抑制剂的相关耐药机制以及联合用药策略。
